Onkológia 5/2014
Targeted terapy of gastric cancer
The incidence of gastric cancer has been declining globally but mortality remains high. 80 % are diagnosed at an advanced stage, when the tumour is inoperabile. Protein HER2/neu is overexpressed in 10 – 15 % of advanced gastric cancers. It is a result of HER2/neu gene amplification. Trastuzumab has become a standard treatment for patients with HER-2 positive advanced gastric cancer.
Keywords: gastric cancer, targeted therapy, HER2 overexpression, trastuzumab.
